|
1
|
Jones OP, Melling JD and Ghaneh P:
Adjuvant therapy in pancreatic cancer. World J Gastroenterol.
20:14733–14746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silvestris N, Gnoni A, Brunetti AE,
Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso
V, Nardulli P, et al: Target therapies in pancreatic carcinoma.
Curr Med Chem. 21:948–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thota R, Pauff JM and Berlin JD: Treatment
of metastatic pancreatic adenocarcinoma: a review. Oncology
(Williston Park). 28:70–74. 2014.PubMed/NCBI
|
|
6
|
Lima CM Rocha, Green MR, Rotche R, Miller
WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and
Miller LL: Irinotecan plus gemcitabine results in no survival
advantage compared with gemcitabine monotherapy in patients with
locally advanced or metastatic pancreatic cancer despite increased
tumor response rate. J Clin Oncol. 22:3776–3783. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T and Zhao Y: MiR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Hajeili M, Azmi AS and Choi M:
Nab-paclitaxel: potential for the treatment of advanced pancreatic
cancer. Onco Targets Ther. 7:187–192. 2014.PubMed/NCBI
|
|
9
|
Chiorean EG and Von Hoff DD: Taxanes:
impact on pancreatic cancer. Anticancer Drugs. 25:584–592. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sherman MH, Yu RT, Engle DD, Ding N,
Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S,
et al: Vitamin D receptor-mediated stromal reprogramming suppresses
pancreatitis and enhances pancreatic cancer therapy. Cell.
159:80–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Li D, Zheng X, Wang E and Wang J:
Selective induction of apoptosis: promising therapy in pancreatic
cancer. Curr Pharm Des. 19:2259–2268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bianco R, Melisi D, Ciardiello F and
Tortora G: Key cancer cell signal transduction pathways as
therapeutic targets. Eur J Cancer. 42:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nicholson DW: From bench to clinic with
apoptosis-based therapeutic agents. Nature. 407:810–816. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao C, Qiao Y, Jonsson P, Wang J, Xu L,
Rouhi P, Sinha I, Cao Y, Williams C and Dahlman-Wright K:
Genome-wide profiling of AP-1-regulated transcription provides
insights into the invasiveness of triple-negative breast cancer.
Cancer Res. 74:3983–3994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaulian E: AP-1 - the Jun proteins:
oncogenes or tumor suppressors in disguise? Cell Signal.
22:894–899. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chinenov Y and Kerppol TK: Close
encounters of many kinds: Fos-Jun interactions that mediate
transcription regulatory specificity. Oncogene. 20:2438–2452. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kolbus A, Herr I, Schreiber M, Debatin KM,
Wagner EF and Angel P: c-Jun-dependent CD95-L expression is a
rate-limiting step in the induction of apoptosis by alkylating
agents. Mol Cell Biol. 20:575–582. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren X, Song W, Liu W, Guan X, Miao F, Miao
S and Wang L: Rhomboid domain containing 1 inhibits cell apoptosis
by upregulating AP-1 activity and its downstream target Bcl-3. FEBS
Lett. 587:1793–1798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi R, Peng H, Yuan X, Zhang X, Zhang Y,
Fan D, Liu X and Xiong D: Down-regulation of c-fos by shRNA
sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic
agents via P-glycoprotein inhibition and apoptosis augmentation. J
Cell Biochem. 114:1890–1900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leijen S, Veltkamp SA, Huitema AD, van
Werkhoven E, Beijnen JH and Schellens JH: Phase I dose-escalation
study and population pharmacokinetic analysis of fixed dose rate
gemcitabine plus carboplatin as second-line therapy in patients
with ovarian cancer. Gynecol Oncol. 130:511–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng Q and Xia Y: c-Jun, at the crossroad
of the signaling network. Protein Cell. 2:889–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Passegué E, Jochum W, Schorpp-Kistner M,
Möhle-Steinlein U and Wagner EF: Chronic myeloid leukemia with
increased granulocyte progenitors in mice lacking junB expression
in the myeloid lineage. Cell. 104:21–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kashatus D, Cogswell P and Baldwin AS:
Expression of the Bcl-3 proto-oncogene suppresses p53 activation.
Genes Dev. 20:225–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Liang X and Yang X: Ursolic acid
inhibits growth and induces apoptosis in gemcitabine-resistant
human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Oncol Rep. 28:501–510. 2012.PubMed/NCBI
|
|
25
|
Dai MH, Liu SL, Chen NG, Zhang TP, You L,
Q Zhang F, Chou TC, Szalay AA, Fong Y and Zhao YP: Oncolytic
vaccinia virus in combination with radiation shows synergistic
antitumor efficacy in pancreatic cancer. Cancer Lett. 344:282–290.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chugh R, Sangwan V, Patil SP, Dudeja V,
Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers
SM and Saluja AK: A preclinical evaluation of Minnelide as a
therapeutic agent against pancreatic cancer. Sci Transl Med.
4:156ra1392012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trouilloud I, Dubreuil O, Boussaha T,
Lepère C, Landi B, Zaanan A, Bachet JB and Taieb J: Medical
treatment of pancreatic cancer: new hopes after 10 years of
gemcitabine. Clin Res Hepatol Gastroenterol. 35:364–374. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JG and Wu R: Erlotinib-cisplatin
combination inhibits growth and angiogenesis through c-MYC and
HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia.
17:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Elmore S: Apoptosis: a review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Evans GL and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo
HC, Wang ZH and Lin SZ: Oridonin enhances antitumor activity of
gemcitabine in pancreatic cancer through MAPK-p38 signaling
pathway. Int J Oncol. 41:949–958. 2012.PubMed/NCBI
|
|
32
|
Teraishi F, Zhang L, Guo W, Dong F, Davis
JJ, Lin A and Fang B: Activation of c-Jun NH2-terminal kinase is
required for gemcitabine's cytotoxic effect in human lung cancer
H1299 cells. FEBS Lett. 579:6681–6687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang XL, Lin FJ, Guo YJ, Shao ZM and Ou
ZL: Gemcitabine resistance in breast cancer cells regulated by
PI3K/AKT-mediated cellular proliferation exerts negative feedback
via the MEK/MAPK and mTOR pathways. Onco Targets Ther. 7:1033–1042.
2014.PubMed/NCBI
|
|
34
|
Wang H, Yang YB, Shen HM, Gu J, Li T and
Li XM: ABT-737 induces Bim expression via JNK signaling pathway and
its effect on the radiation sensitivity of HeLa cells. PLoS One.
7:e524832012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rebollo A, Dumoutier L, Renauld JC,
Zaballos A, Ayllón V and Martínez-A C: Bcl-3 expression promotes
cell survival following interleukin-4 deprivation and is controlled
by AP1 and AP1-like transcription factors. Mol Cell Biol.
20:3407–3416. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang W, Du Z, Yan J, Ma D, Shi M, Zhang M,
Peng C and Li H: Mesenchymal stem cells promote liver regeneration
and prolong survival in small-for-size liver grafts: involvement of
C-Jun N-terminal kinase, cyclin D1, and NF-κB. PLoS One.
9:e1125322014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niu Q, Liu H, Guan Z, Zeng Q, Guo S, He P,
Guo L, Gao P, Xu B, Xu Z, et al: The effect of c-Fos demethylation
on sodium fluoride-induced apoptosis in L-02 cells. Biol Trace Elem
Res. 149:102–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Renaud SJ, Kubota K, Rumi MA and Soares
MJ: The FOS transcription factor family differentially controls
trophoblast migration and invasion. J Biol Chem. 289:5025–5039.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ganesan V and Colombini M: Regulation of
ceramide channels by Bcl-2 family proteins. FEBS Lett.
584:2128–2134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Smith SC, Petrova AV, Madden MZ, Wang H,
Pan Y, Warren MD, Hardy CW, Liang D, Liu EA, Robinson MH, et al: A
gemcitabine sensitivity screen identifies a role for NEK9 in the
replication stress response. Nucleic Acids Res. 42:11517–11527.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gautam S, Kirschnek S, Wiesmeier M, Vier J
and Häcker G: Roscovitine-induced apoptosis in neutrophils and
neutrophil progenitors is regulated by the Bcl-2-family members
Bim, Puma, Noxa and Mcl-1. PLoS One. 8:e793522013. View Article : Google Scholar : PubMed/NCBI
|
